Enzalutamide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Castration-Resistant Prostate Cancer
Conditions
Castration-Resistant Prostate Cancer
Trial Timeline
Sep 30, 2009 → Nov 2, 2017
NCT ID
NCT00974311About Enzalutamide + Placebo
Enzalutamide + Placebo is a phase 3 stage product being developed by Astellas Pharma for Castration-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00974311. Target conditions include Castration-Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02677896 | Phase 3 | Completed |
| NCT02528643 | Phase 2 | Completed |
| NCT02294461 | Phase 3 | Completed |
| NCT02003924 | Phase 3 | Completed |
| NCT01212991 | Phase 3 | Completed |
| NCT00974311 | Phase 3 | Completed |
Competing Products
20 competing products in Castration-Resistant Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SRF617 + etrumadenant + zimberelimab | Coherus BioSciences | Phase 2 | 44 |
| Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication | Daiichi Sankyo | Phase 1/2 | 41 |
| Valemetostat + Darolutamide | Daiichi Sankyo | Phase 1 | 33 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| enzalutamide + abiraterone acetate + prednisone | Astellas Pharma | Phase 2 | 52 |
| Crizotinib + Enzalutamide | Astellas Pharma | Phase 1 | 33 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Lu-PSMA + Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Approved | 85 |
| enzalutamide | Astellas Pharma | Pre-clinical | 23 |
| Enzalutamide + Flutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide + Abiraterone acetate | Astellas Pharma | Pre-clinical | 23 |
| Enzalutamide | Astellas Pharma | Approved | 85 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| MDV3100 | Astellas Pharma | Pre-clinical | 23 |
| ZEN003694 + Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide + Placebo | Astellas Pharma | Phase 3 | 77 |